AR002709A1 - Un proceso para preparar una forma cristalina del loracarbef monohidrato y una forma cristalina de loracarbef anhidrato util para preparar dichomonohidrato con dicho procedimiento. - Google Patents
Un proceso para preparar una forma cristalina del loracarbef monohidrato y una forma cristalina de loracarbef anhidrato util para preparar dichomonohidrato con dicho procedimiento.Info
- Publication number
- AR002709A1 AR002709A1 ARP960101460A AR10146096A AR002709A1 AR 002709 A1 AR002709 A1 AR 002709A1 AR P960101460 A ARP960101460 A AR P960101460A AR 10146096 A AR10146096 A AR 10146096A AR 002709 A1 AR002709 A1 AR 002709A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline form
- prepare
- loracarbef
- approximately
- anhydrate
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229960001977 loracarbef Drugs 0.000 title abstract 2
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6r,7s)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000002178 crystalline material Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-M loracarbef anion Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)N)=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-M 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D463/14—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hetero atoms directly attached in position 7
- C07D463/16—Nitrogen atoms
- C07D463/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
- C07D463/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D463/22—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se trata de la preparación de un solvato cristalino del anhidrato de Loracarbef de fórmula (I), cuyo diagrama de difracción Rx (en polvo) se ilustraen la descripción. Dicho proceso comprende: a) exponer una forma cristalina anhidratada delcompuesto de la fórmula (I), a una humedad relativa deaproximadamente 90 a aproximadamente 100%, a efectos de proveer una forma cristalina monohidratada del compuesto de la fórmula (I),que tiene un contenidode agua superior o igual al 10%;y b)secar el material cristalino monohidratado a una temperatura de aproximadamente 55°C a aproximadamente 75°C bajo unapresión de aproximadamente 20 mbar a aproximadamente 50 mbar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/396,948 US5580977A (en) | 1995-03-01 | 1995-03-01 | Process for preparing loracarbef monohydrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR002709A1 true AR002709A1 (es) | 1998-04-29 |
Family
ID=23569249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960101460A AR002709A1 (es) | 1995-03-01 | 1996-02-21 | Un proceso para preparar una forma cristalina del loracarbef monohidrato y una forma cristalina de loracarbef anhidrato util para preparar dichomonohidrato con dicho procedimiento. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5580977A (es) |
| EP (1) | EP0729959B1 (es) |
| JP (1) | JPH11501032A (es) |
| KR (1) | KR19980702666A (es) |
| CN (1) | CN1061349C (es) |
| AR (1) | AR002709A1 (es) |
| AT (1) | ATE184006T1 (es) |
| AU (1) | AU694639B2 (es) |
| BR (1) | BR9607308A (es) |
| CA (1) | CA2213812A1 (es) |
| CO (1) | CO4700429A1 (es) |
| CZ (1) | CZ272897A3 (es) |
| DE (1) | DE69603995T2 (es) |
| DK (1) | DK0729959T3 (es) |
| ES (1) | ES2135165T3 (es) |
| GR (1) | GR3031947T3 (es) |
| HU (1) | HUP9702151A3 (es) |
| IL (1) | IL117228A (es) |
| NO (1) | NO308471B1 (es) |
| NZ (1) | NZ304534A (es) |
| PE (1) | PE28097A1 (es) |
| PL (1) | PL322111A1 (es) |
| RU (1) | RU2160261C2 (es) |
| SI (1) | SI0729959T1 (es) |
| TR (1) | TR199700877T1 (es) |
| TW (1) | TW330205B (es) |
| WO (1) | WO1996026942A1 (es) |
| ZA (1) | ZA961341B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100540046B1 (ko) | 1997-11-12 | 2006-01-10 | 미쓰비시 가가꾸 가부시키가이샤 | 퓨린유도체 및 이를 유효성분으로 함유하는 의약 |
| JP3956188B2 (ja) | 1999-05-11 | 2007-08-08 | 三菱化学株式会社 | プリン誘導体２水和物、それを有効成分として含む医薬およびその製造中間体 |
| US6410520B2 (en) | 2000-02-01 | 2002-06-25 | The Procter & Gamble Company | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| PE20011065A1 (es) | 2000-02-01 | 2001-11-21 | Procter & Gamble | Proceso para fabricar bisfosfonatos geminales |
| US20060205938A1 (en) * | 2002-11-21 | 2006-09-14 | Yatendra Kumar | Monohydrate solvates of loracarbef |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3531481A (en) * | 1969-04-21 | 1970-09-29 | Lilly Co Eli | Method for manufacture of crystalline cephalosporin |
| US3502663A (en) * | 1969-04-21 | 1970-03-24 | Lilly Co Eli | Crystalline cephalosporin,method for its manufacture |
| US4775751A (en) * | 1985-06-03 | 1988-10-04 | Eli Lilly & Company | Process for cephalexin hydrochloride alcoholates |
| YU46699B (sh) * | 1987-10-06 | 1994-04-05 | Eli Lilly And Co. | Kristalni monohidratni oblik 1-karbacefalosporina |
| US4977257A (en) * | 1988-11-14 | 1990-12-11 | Eli Lilly And Company | DMF solvates of a β-lactam antibiotic |
| CA2002596A1 (en) * | 1988-11-14 | 1990-05-14 | Thomas M. Eckrich | Hydrates of b-lactam antibiotic |
| CA2002597C (en) * | 1988-11-14 | 1999-03-23 | Thomas M. Eckrich | Solvates of b-lactam antibiotic |
| US5352782A (en) * | 1993-06-04 | 1994-10-04 | Eli Lilly And Company | Process for preparing crystalline β-lactam monohydrate |
| US5399686A (en) * | 1993-06-04 | 1995-03-21 | Eli Lilly And Company | Loracarbef isopropanolate and a process for converting loracarbef isopropanolate to loracarbef monohydrate |
| US5374719A (en) * | 1993-06-04 | 1994-12-20 | Eli Lilly And Company | Process for converting loracarbef dihydrate to loracarbef monohydrate |
-
1995
- 1995-03-01 US US08/396,948 patent/US5580977A/en not_active Expired - Lifetime
-
1996
- 1996-02-20 ZA ZA9601341A patent/ZA961341B/xx unknown
- 1996-02-21 AR ARP960101460A patent/AR002709A1/es not_active Application Discontinuation
- 1996-02-22 IL IL11722896A patent/IL117228A/xx active IP Right Grant
- 1996-02-24 TW TW085102100A patent/TW330205B/zh active
- 1996-02-26 PE PE1996000129A patent/PE28097A1/es not_active Application Discontinuation
- 1996-02-26 CO CO96008863A patent/CO4700429A1/es unknown
- 1996-02-27 ES ES96301303T patent/ES2135165T3/es not_active Expired - Lifetime
- 1996-02-27 SI SI9630108T patent/SI0729959T1/xx not_active IP Right Cessation
- 1996-02-27 EP EP96301303A patent/EP0729959B1/en not_active Expired - Lifetime
- 1996-02-27 AT AT96301303T patent/ATE184006T1/de not_active IP Right Cessation
- 1996-02-27 DE DE69603995T patent/DE69603995T2/de not_active Expired - Fee Related
- 1996-02-27 DK DK96301303T patent/DK0729959T3/da active
- 1996-02-28 BR BR9607308A patent/BR9607308A/pt not_active Application Discontinuation
- 1996-02-28 CN CN96193438A patent/CN1061349C/zh not_active Expired - Fee Related
- 1996-02-28 NZ NZ304534A patent/NZ304534A/en unknown
- 1996-02-28 JP JP8526365A patent/JPH11501032A/ja not_active Ceased
- 1996-02-28 KR KR1019970706072A patent/KR19980702666A/ko not_active Abandoned
- 1996-02-28 AU AU51742/96A patent/AU694639B2/en not_active Ceased
- 1996-02-28 PL PL96322111A patent/PL322111A1/xx unknown
- 1996-02-28 TR TR97/00877T patent/TR199700877T1/xx unknown
- 1996-02-28 CA CA002213812A patent/CA2213812A1/en not_active Abandoned
- 1996-02-28 WO PCT/US1996/002586 patent/WO1996026942A1/en not_active Ceased
- 1996-02-28 HU HU9702151A patent/HUP9702151A3/hu unknown
- 1996-02-28 CZ CZ972728A patent/CZ272897A3/cs unknown
- 1996-02-28 RU RU97116165/04A patent/RU2160261C2/ru active
-
1997
- 1997-08-20 NO NO973835A patent/NO308471B1/no not_active IP Right Cessation
-
1999
- 1999-11-25 GR GR990403040T patent/GR3031947T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199901578T2 (xx) | Klaritromisin form 0 kristali | |
| FI833339A0 (fi) | Foerfarande foer framstaellning av farmakologiskt verksamma diazabicyklo-(3,3,1)-nonaner | |
| HUP9600876A2 (hu) | Benzonitril- és -fluorid-származékok, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk | |
| JPS5219869A (en) | Reservoir tank for master cylinder | |
| DE59307841D1 (de) | Sulfoalkylgruppenhaltige Alkylhydroxyalkylcelluloseether | |
| AR218604A1 (es) | Nuevos compuestos derivados de 1-(benzoilo 2,6-disustituidos)-3-(pirazinilo o quinoxalinilo)urea,procedimiento para su produccion y composicion insecticida que los contiene | |
| AR002709A1 (es) | Un proceso para preparar una forma cristalina del loracarbef monohidrato y una forma cristalina de loracarbef anhidrato util para preparar dichomonohidrato con dicho procedimiento. | |
| HUP9701660A2 (hu) | 10,13,15-trioxa-triciklo[9.2.1.1. 9.6]pentadekanon-származékok, eljárás ezek előállítására, és az e vegyületeket tartalmazó gyógyászati készítmények | |
| ES8104245A1 (es) | Procedimiento para la preparacion de derivados de bencimida-zol | |
| DK35882A (da) | Indanylderivater og fremgangsmaade til fremstilling deraf | |
| NO154793C (no) | Fremgangsmaate til fjerning av urenheter fra natriumaluminatopploesninger. | |
| SE410304B (sv) | Lagtrycksforfarande for framstellning av beta-litiumaluminat | |
| FI852951L (fi) | Kemisk syntes. | |
| IT1203052B (it) | Procedimento per la produzione di gas di sintesi o di gas combustibile | |
| DE3161462D1 (en) | Cephalosporins, processes for their preparation and pharmaceutical compositions containing these compounds | |
| KR950000701A (ko) | 로라카베프 이수화물을 로라카베프 일수화물로 전환시키는 방법 | |
| NO154012C (no) | Nye benzisotiazolderivater, soetningsmiddelpreparater inneholdende dem og anvendelse av forbindelsene som soetningsmidler. | |
| JPS51126399A (en) | Purification of sodium hydroxide | |
| JPS5285164A (en) | Preparatin of maleinimide compounds | |
| JPS5629579A (en) | Preparation of novel cyclic urethane compound | |
| JPS5317873A (en) | Master cylinder | |
| JPS51123064A (en) | Forming process of bonding-pad area | |
| JPS5219669A (en) | Preparation of tetrazole derivatives and acid addition salts thereof | |
| IT7926546A0 (it) | Urea. procedimento per eliminare l'esplosivita' dei gas di spurgo da impianti per la produzione di | |
| JPS55143977A (en) | 1,3-diazepin derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |